EMD Millipore entered into a collaboration with celares to offer pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering includes feasibility studies, process and analytical development, and scaleup from milligram to gram quantities required for pilot and subsequent commercial scale.

“While a widely used approach to improving drug delivery, a successful pegylation strategy is dependent upon materials expertise and application experience,” explained Andrew Bulpin, executive vp of process solutions at EMD Millipore. “celares is a recognized leader in this area and through our collaboration, we are now able to expand our service offering to include conjugation, further helping our biopharmaceutical and biosimiliar customers to optimize their protein therapeutics and to reduce their time to market.”

The new services will leverage EMD Millipore's broad range of functionalized PEG products of different molecular weight and activation chemistry, as well as buffers, solvents and excipients, unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography, according to Bulpin.

“An optimized formulation can help a promising protein therapeutic reach the clinic and patients in need,” noted Frank Leenders, Ph.D., managing director of operations at celares. “Our expertise in pegylation combined with the experience and integrated products and unit operations from EMD Millipore will create customized solutions needed by the biopharmaceutical industry to maintain forward progress of promising drug candidates.”

Previous articleDNA Ambulance Transports to Hospital of Inefficient Repair
Next articleGenzyme to Buy Caprelsa from AstraZeneca for Up to $300M